Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events.
Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Fujisaki T, et al. Among authors: matsumoto n. Front Oncol. 2021 Sep 24;11:704475. doi: 10.3389/fonc.2021.704475. eCollection 2021. Front Oncol. 2021. PMID: 34631533 Free PMC article.
Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K, Kondo R, Koyama K, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Tsukada H, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Saida Y, et al. Among authors: matsumoto n. Thorac Cancer. 2019 Nov;10(11):2106-2116. doi: 10.1111/1759-7714.13189. Epub 2019 Sep 10. Thorac Cancer. 2019. PMID: 31507098 Free PMC article.
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).
Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. Okajima M, et al. Among authors: matsumoto n. Transl Lung Cancer Res. 2021 Jan;10(1):252-260. doi: 10.21037/tlcr-20-649. Transl Lung Cancer Res. 2021. PMID: 33569309 Free PMC article.
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.
Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K, Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K, Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Koyama K, et al. Among authors: matsumoto n. Sci Rep. 2022 Apr 16;12(1):6367. doi: 10.1038/s41598-022-10288-8. Sci Rep. 2022. PMID: 35430596 Free PMC article.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T, Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Shoji S, et al. Among authors: matsumoto n. Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi: 10.21037/tlcr-22-89. Transl Lung Cancer Res. 2022. PMID: 35958345 Free PMC article.
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients.
Kushiro K, Watanabe S, Goto Y, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Tanaka T, Saida Y, Sato Y, Ota T, Koshio J, Hayashi Y, Miyabayashi T, Matsumoto N, Ichikawa K, Koyama K, Kikuchi T. Kushiro K, et al. Among authors: matsumoto n. Transl Lung Cancer Res. 2022 Sep;11(9):1858-1865. doi: 10.21037/tlcr-22-225. Transl Lung Cancer Res. 2022. PMID: 36248339 Free PMC article.
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T. Watanabe S, et al. Among authors: matsumoto n. Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204. Cancers (Basel). 2022. PMID: 36612200 Free PMC article.
3,338 results